ReviewJournal of the Canadian Association of Gastroenterology2023
The 2023 Impact of Inflammatory Bowel Disease in Canada: Indirect (Individual and Societal) and Direct Out-of-Pocket Costs.
Review in Journal of the Canadian Association of Gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 17 citations in OpenAlex.
- Impact of an intervention program on drug adherence in patients with ulcerative colitis: Randomized clinical trial.PloS one · 2023Trial
- Work Productivity Loss and Activity Impairment in Parents of Children With Juvenile Idiopathic Arthritis.ACR open rheumatology · 2026Article
- Nationalization of clinical care pathways for inflammatory bowel disease management in Canada.Journal of the Canadian Association of Gastroenterology · 2026Article
- Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in inflammatory bowel disease.World journal of gastroenterology · 2025Observational
- Models of outpatient care delivery in inflammatory bowel disease: a scoping review.Journal of the Canadian Association of Gastroenterology · 2025Article
- The global burden of inflammatory bowel disease: from 2025 to 2045.Nature reviews. Gastroenterology & hepatology · 2025Review
- Engineered spermidine-secreting Saccharomyces boulardii ameliorates colitis and colon cancer in mice.Scientific reports · 2025Article
- Article
- Compounding Prevalence of Inflammatory Bowel Disease in a 2024 Population-Based Study From Canterbury, New Zealand.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- Machine learning prediction of premature death from multimorbidity among people with inflammatory bowel disease: a population-based retrospective cohort study.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025Article
- Incidence of Inflammatory Bowel Disease in Canterbury, New Zealand, 2018-2023.Digestive diseases and sciences · 2025Article
- Transition to Subcutaneous Infliximab vs Vedolizumab in Inflammatory Bowel Disease: A Prospective Multicenter Study.Digestive diseases and sciences · 2024Observational
- Chronic Abdominal Pain in Patients with Inflammatory Bowel Disease in Remission: A Continuing Challenge for Clinicians.Digestive diseases and sciences · 2024Review
- Rural Residence Is Associated With Telephone Care Satisfaction Among Individuals With Inflammatory Bowel Disease: Cross-Sectional Study From Saskatchewan, Canada.Inquiry : a journal of medical care organization, provision and financingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 12 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
People living with inflammatory bowel disease (IBD) and their caregivers are faced with indirect and out-of-pocket costs that they would not otherwise experience. These costs impact one's ability to contribute to the economy to their fullest potential. The indirect costs of IBD in Canada are estimated to be at least $1.51 billion in 2023 and include costs associated with lost productivity resulting from a combination of missed work (absenteeism), decreased workplace productivity (presenteeism), unemployment, premature mortality, and caregiving costs. Unemployment is the largest contributor to indirect costs ($1.14 billion), followed by costs of absenteeism and presenteeism ($285 million). Caregiving costs for children with IBD are estimated to be nearly $58 million. Canadians with IBD also pay $536 million every year for care that is not covered by universal or supplemental private health insurance; this includes allied healthcare (e.g., care provided by psychologists), medication, and other supportive therapy. Combined, the indirect and out-of-pocket costs of IBD in Canada are estimated at more than $2 billion CAD in 2023. This is substantially higher than the estimate of $1.29 billion in Crohn's and Colitis Canada's 2018 Impact of IBD report with differences attributable to a combination of rising prevalence, inflation, and the addition of presenteeism and caregiving costs to the total indirect costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.